Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,322 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Diseases Clear all
Completed Phase 2 Interventional Results available

Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)

NCT00529191
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

NCT04183790
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery

NCT01646697
View directory record Official record
Conditions
Pancreatic Cancer, Adenocarcinoma
Interventions
cytology specimen collection procedure
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

NCT06154447
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
12
States / cities
Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

NCT07223047
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Not listed Phase 1Phase 2 Interventional

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

NCT02038738
View directory record Official record
Conditions
Neuroendocrine, Neuroendocrine Tumor, Neuroendocrine Cancer, Neuroendocrine Carcinoma, Carcinoid, Carcinoid Tumor, Islet Cell Tumor, Apudoma
Interventions
68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Kenner, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 15, 2026, 2:05 AM EDT
Terminated Phase 3 Interventional Results available

Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

NCT01774604
View directory record Official record
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Indomethacin, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

NCT04431258
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ABTL0812, Folfirinox, Placebo
Drug
Lead sponsor
Ability Pharmaceuticals SL
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 15, 2026, 2:05 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

NCT05610826
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumor, Pancreas Cancer
Interventions
cytoreductive surgery, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT), Peptide receptor radionuclide therapy (PRRT)
Procedure · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 15, 2026, 2:05 AM EDT
Active, not recruiting No phase listed Observational

A Pilot Study in Endoscopic Therapy on Quality of Life and Pain in Chronic Pancreatitis

NCT05012150
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 15, 2026, 2:05 AM EDT
Recruiting Phase 1 Interventional

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

NCT06411691
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
KRAS Vaccine with Poly-ICLC adjuvant, Balstilimab, Botensilimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
Mario Castro, MD, MPH
Other
Eligibility
3 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study

NCT01973413
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs), Tandem t:slim Insulin Pump, Dexcom G4 Platinum sensor
Device
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Los Gatos, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 15, 2026, 2:05 AM EDT
Not listed Phase 3 Interventional

PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen

NCT00088660
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PANVAC™-VF
Biological
Lead sponsor
Therion Biologics Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
62
States / cities
Mobile, Alabama • La Jolla, California • Long Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2006 · Synced Oct 15, 2026, 2:05 AM EDT
Recruiting No phase listed Observational

Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis

NCT06560463
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Interventions
Access to Dexcom G7 CGM Data
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

Study of INCA 0186 in Subjects With Advanced Solid Tumors

NCT04989387
View directory record Official record
Conditions
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
Interventions
INCA00186, Retifanlimab, INCB106385
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Results available

A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas

NCT00711191
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
monoclonal antibody, chemotherapy
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 15, 2026, 2:05 AM EDT
Recruiting Not applicable Interventional

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

NCT05679674
View directory record Official record
Conditions
Pancreas Cancer, Locally Advanced, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Stereotactic Ablative Body Radiation (SABR), Tumor Treating Fields (TTF)
Radiation · Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

NCT00120939
View directory record Official record
Conditions
Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Oct 15, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer

NCT00121745
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Rexin-G Dose 1, Rexin-G Dose 2, Rexin-G Dose 3, Rexin-G Dose 4
Genetic
Lead sponsor
Epeius Biotechnologies
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer

NCT00059826
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
interferon-alfa-2b, cisplatin, 5-fluorouracil, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
14
States / cities
Gainesville, Florida • Chicago, Illinois • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

NCT01420874
View directory record Official record
Conditions
Colorectal Cancer, Cancer of Pancreas, Pancreatic Neoplasm, Malignant Neoplasm of Large Intestine, Malignant Tumor of Colon, Colon Carcinoma, Cancer of Colon, Pancreatic Cancer
Interventions
FOLFOX6, EGFRBi armed ATC Infusions
Drug · Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Zinc Supplements in Lowering Cadmium Levels in Smokers

NCT00376987
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
zinc oxide
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 120 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 15, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Nurse-Provided Care or Standard Care in Treating Patients With Pancreatic Cancer

NCT00902733
View directory record Official record
Conditions
Fatigue, Nausea and Vomiting, Pain, Pancreatic Cancer
Interventions
medical chart review, questionnaire administration, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2010 · Synced Oct 15, 2026, 2:05 AM EDT